Still Eyeing IPO, Quark Says Cost Expectations for Rx Pipeline Exceed $54M | GenomeWeb

By Doug Macron

Quark Pharmaceuticals last week released some additional details about its proposed US initial public offering, indicating that it is hoping to raise enough capital to help cover the more than $54 million it will take to conduct phase I and II trials for its lead product candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: transcriptional map of human embryo development, circadian clock genes in acute myeloid leukemia, and more.

The US National Academy of Sciences has announced 84 new members and 21 foreign associates.

The users of file-sharing site Sci-Hub work all around the globe where research is going on, Science's John Bohannon reports.

Researchers link obesity in Labrador retrievers to a deletion in their POMC gene.